Dermatology Research and Practice

Volume 2014 (2014), Article ID 953597, 5 pages

http://dx.doi.org/10.1155/2014/953597

Research Article

IL-1RN VNTR Polymorphism in Adult Dermatomyositis and Systemic Lupus Erythematosus

Zornitsa Kamenarska,¹ Gyulnas Dzhebir,¹ Maria Hristova,² Alexey Savov,³ Anton Vinkov,⁴ Radka Kaneva,¹ Vanio Mitev,¹ and Lyubomir Dourmishev⁵

¹Molecular Medicine Center and Department of Medical Chemistry and Biochemistry, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria

²Department of Clinical Laboratory and Clinical Immunology and Department of Nephrology, Medical University-Sofia, 1 Georgi Sofijski Street, 1431 Sofia, Bulgaria

³National Genetic Laboratory, Maichin Dom Hospital, 2 Zdrave Street, 1431 Sofia, Bulgaria

⁴28 Diagnostic and Consultative Center-Sofia, 1 Iliya Beshkov Street, 1592 Sofia, Bulgaria

⁵Department of Dermatology and Venereology, Medical University-Sofia, 1 Georgi Sofijski Street, 1431 Sofia, Bulgaria

Received 14 June 2014; Accepted 7 August 2014; Published 19 August 2014

Academic Editor: Elizabeth Helen Kemp

Copyright © 2014 Zornitsa Kamenarska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Polymorphisms in the cytokine genes and their natural antagonists are thought to influence the predisposition to dermatomyositis (DM) and systemic lupus erythematosus (SLE). A variable number tandem repeat (VNTR) polymorphism of 86 bp in intron 2 of the interleukin-1 receptor antagonist (IL-1RN) gene leads to the existence of five different alleles which cause differences in the production of both IL-1RA (interleukin-1 receptor antagonist) and IL-1β. The aim of this case-control study was to investigate the association between the IL-1RN VNTR polymorphism and the susceptibility to DM and SLE in Bulgarian patients. Altogether 91 patients, 55 with SLE and 36 with DM, as well as 112 unrelated healthy controls, were included in this study. Only three alleles were identified in both patients and controls ((1) four repeats, (2) two repeats, and (3) five repeats). The IL-2 allele (, OR 2.5, and 95% CI 1.2–5.4) and the 1/2+2/2 genotypes were found prevalent among the SLE patients (, OR 2.6, and 95% CI 1–6.3). No association was found between this polymorphism and the ACR criteria for SLE as well as with the susceptibility to DM. Our results indicate that the IL-1RN VNTR polymorphism might play a role in the susceptibility of SLE but not DM.

1. Introduction

Dermatomyositis (DM) and systemic lupus erythematosus (SLE) are diseases of unknown etiology. However, the dysregulation of cytokine production or action is thought to have an important role in their development [1].

Interleukin-1α (IL-1α) and interleukin-1β (IL-1β) are proinflammatory cytokines which belong to the IL-1 family. The interleukin-1 receptor antagonist (IL-1RA) is a naturally occurring competitive inhibitor of IL-1. The dysregulation of IL-1 production caused by IL-1RA leads to abnormal inflammatory activity which results in subsequent tissue damage commonly observed in the pathogenesis of SLE and DM. The interleukin-1 receptor antagonist (IL-1RN) gene is polymorphic, resulting in quantitative differences in both IL-1RA and IL-1β production. A tandem repeat sequence of 86 base pairs in length was described in intron 2 of the IL-1RN gene [2]. The number of times this sequence is repeated varies from 2 to 6. The most common is allele 1 (four repeats) followed by allele 2 (2 repeats). The other three alleles are rare, found in less than 1% in most populations. IL-2 allele was found associated with increased IL-1RA production in vitro [3]. The serum levels of IL-1RA were found significantly higher in lupus [4] and DM [5, 6] patients than in controls. The higher IL-1RA levels could serve as predictive biomarker for renal involvement in SLE [7] and positively correlated with PM/DM disease activity [8, 9].

The objective of our study was to determine whether the IL-1RN VNTR polymorphism is a risk factor for the development of adult DM and SLE in Bulgarian patients and to define its contribution to the increased risk.

2. Materials and Methods

2.1. Patient Population

Thirty-six patients with dermatomyositis who met the criteria of Bohan and Peter [10, 11] and Targoff et al. [12] and fifty-five with systemic lupus erythematosus who met the American College of Rheumatology (ACR) criteria were included in this study. Only patients with definite or probable disease were included. The clinical and demographic data are presented in Table 1. In the DM group, 23 patients were female and 13 male. The mean age was 52 with a range of 18–82 years. In the SLE group, 46 were female and 9 male. The mean age was 40 with a range of 15–78 years. The patients have been followed for a mean of 10 years at the Department of Dermatology and Venereology, Medical University-Sofia, at the Department of Nephrology, Medical University-Sofia, and at the Department of Nephrology, Ministry of Interior Hospital-Sofia.

Table 1: Demographic and clinical data.

Disease
DM
SLE

Demographic parameters
Female/male
23/13
Female/male
46/9

Age, mean ± SD years
52 ± 14.7
Age, mean ± SD years
40 ± 12.4

Clinical parameters
Cutaneous disease

Muscle weakness

Elevated muscle enzymes

EMG findings

Photosensitivity

Autoantibodies
27 (78.8%)

28 (78.8%)

19 (54.6%)

20 (54.6%)

21 (60.6%)

9 (18.2%)
Malar rash

Discoid rash

Arthritis

Oral ulcer

Photosensitivity

Serositis

Renal disease

Neurological disease

Haematological disease

Immunological disease

ANA
34 (61.8%)

11 (20.0%)

37 (67.3%)

4 (7.3%)

31 (56.4%)

11 (20.0%)

55 (100%)

12 (22.2%)

20 (36.4%)

34 (61.8%)

39 (70.9%)

SD: standard deviation, EMG: electromyography, and ANA: antinuclear antibodies.

The control group consisted of 112 anonymous healthy volunteers who did not show any clinical or laboratory signs of autoimmune skin diseases, as well as kinship with patients suffering from autoimmune skin diseases. They were randomly selected from the Biobank of the Molecular Medicine Center and the National Genetic Laboratory as to match the patients in age, gender, and ethnicity.

2.2. Genetic Analysis

The scientific investigation presented in this paper has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The study was approved by the local ethics committee at the Medical University-Sofia. All participants signed an informed consent and venous blood was drawn for DNA isolation. Genomic DNA was extracted from the peripheral blood with the Chemagen DNA purification kit, using Chemagic Magnetic Separation Module I (Chemagen AG).

The analysis of IL-1RN 86 bp repeat polymorphism was performed as previously described by Tarlow et al. [2]. Standard primer pairs were used (5′-CTCAGCAACACTCCTAT; 3′-TCCTGGTCTGCAGGTAA). Amplification was performed under the following conditions: denaturing step at 95°C for 10 minutes, 35 cycles of 95°C for 60 seconds, 59°C for 60 seconds, 72°C for 60 seconds, and 1 cycle of extension at 72°C for 10 minutes. The products were visualized on a 3% agarose gel stained with ethidium bromide.

2.3. Statistical Analysis

Allele and genotype frequencies were compared between DM and SLE cases and controls, using Fisher’s exact test to calculate values for 2 × 2 tables. Where significant, data were expressed as value, odds ratios (OR) with exact 95% confidence intervals (CI).

3. Results

The observed allele and genotype frequencies of the IL-1RN VNTR polymorphism among the patients with DM, SLE, and the healthy controls are summarized in Table 2.

Table 2: Genotype and allele frequencies of the IL-1RN VNTR polymorphism among patients with DM, SLE, and controls.

Genotype
DM
SLE
Controls

: number of patients

Genotypes

    1/1
33 (91.7%)
41 (74.6%)
96 (85.7%)

    1/2
0 (0.0%)
8 (14.5%)
9 (8.0%)

    2/2
1 (2.8%)
4 (7.3%)
2 (1.8%)

    1/3
2 (5.6)
1 (1.8%)
4 (3.6%)

    2/3
0 (0.0%)
0 (0.0%)
1 (0.9%)

    3/3
0 (0.0%)
1 (1.8%)
0 (0.0%)

     value
NS*
,

Alleles

    1
68 (94.4%)
91 (82.7%)
205 (91.5%)

    2
2 (2.8%)
16 (14.6%)
14 (6.3%)

    3
2 (2.8%)
3 (2.7%)
5 (2.2%)

     value
NS
2,

*NS: not significant.

Only three alleles were detected among the Bulgarian population: 1 (four repeats), 2 (two repeats), and 3 (five repeats). The IL-2 allele (, OR 2.5, and 95% CI 1.2–5.4) and the 12 + 22 genotypes (, OR 2.6, and 95% CI 1–6.3) were found associated with SLE (Table 2).

No association was found between that polymorphism and DM as well as with the clinical manifestations of the two diseases (Table 3).

Table 3: Comparison between the genotypes and the ACR criteria for SLE.

Genotype
1/1 ()
1/2 ()
2/2 ()
1/3 ()
3/3 ()
value

Malar rash
28 (68.3%)
4 (50.0%)
2 (50.0%)
0 (0.0%)
0 (0.0%)
NS*

Discoid rash
7 (17.1%)
3 (37.5%)
1 (25.0%)
0 (0.0%)
0 (0.0%)
NS

Photosensitivity
23 (57.1%)
5 (61.5%)
2 (50.0%)
1 (100.0%)
0 (0.0%)
NS

Oral ulcer
3 (7.3%)
1 (12.5%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
NS

Arthritis
29 (70.7%)
5 (62.5%)
2 (50.0%)
0 (0.0%)
1 (100.0%)
NS

Serositis
10 (24.4%)
1 (12.5%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
NS

Renal disease
41 (100.0%)
8 (100.0%)
4 (100.0%)
1 (100.0%)
1 (100.0%)
NS

Neurological disease
10 (22.9%)
1 (12.5%)
0 (0.0%)
0 (0.0%)
1 (100.0%)
NS

Haematological disease
15 (36.6%)
4 (50.0%)
1 (25.0%)
0 (0.0%)
0 (0.0%)
NS

Immunological disease
24 (58.3%)
5 (62.5%)
3 (75.0%)
1 (100.0%)
1 (100.0%)
NS

(Anti-dsDNA, anti-Sm, anti-phospholipid Ab)

ANA
29 (70.7%)
7 (87.5%)
2 (50.0%)
0 (0.0%)
1 (100.0%)
NS

*Not significant, anti-dsDNA: antibodies to the double stranded DNA, anti-SM: anti-Smith antibodies (specific markers for SLE), and ANA: antinuclear antibodies.

4. Discussion

The majority of the studies relating IL-1RN gene polymorphisms to disease susceptibility have dealt with patients with autoimmune diseases or disorders associated with chronic inflammation [13].

The first study to correlate this polymorphism with SLE susceptibility was done on Caucasians and the carriage of IL-2 allele was reported to be associated with severity rather than susceptibility to SLE [14]. The association strengthened with extensive disease and particularly with the presence of photosensitivity and discoid skin lesions. The association of the IL1-2 allele with SLE was confirmed for Japanese patients and it was again increased with photosensitivity [15]. Similarly, increased frequencies of malar rash and photosensitivity were observed among patients with IL1- compared to patients without the allele [16]. In our study we have not observed any association between that polymorphism and ACR criteria. However, we have observed a higher frequency of the IL-2 allele and 1/2 + 2/2 genotype in patients with SLE which is in line with the results of most of the previous studies [14–18]. Our results correlate well with the results of a recent meta-analysis [19]. In Malaysia, however, the risk allele associated with SLE susceptibility was IL-1 [20] while other authors could not find any association between that polymorphism and SLE [21–23]. Quite surprisingly Mohammadoo-Khorasani et al. [24] found an association between the IL-4 allele and the 1/4 genotype and the development of SLE in Iranian cohort. Such discrepancies could be attributed to interethnic variations [25], low frequency of the IL-2 allele, small sample size which lacks statistical power, or influence of other polymorphisms. Furthermore, it was shown that IL-1RA 2/2 was not individually associated with SLE but the combination of the FcγRIIa R/R and IL-1RN 2/2 genotypes is associated with SLE in Caucasian patients [26]. The studies concerning the polymorphisms in the IL-1RN gene could have practical aspects since they might affect the response towards Anakinra, which is a recombinant form of human IL-1RA [27].

The frequency of the IL-2 allele was low among the DM patients and no statistically significant associations were found in allele and genotype distribution. Our results correlate with the results of other authors [8]. Interestingly Rider et al. [28] have found the IL-1 allele being associated with juvenile idiopathic inflammatory myopathies (JIIM) in Caucasians, while the IL-3 allele was associated with JIIM in African-Americans.

In summary, our results indicate that IL-1RN VNTR polymorphism might play a role in the susceptibility of SLE but not DM in Bulgarian patients.

Conflict of Interests

The authors state no conflict of interests.

Acknowledgments

The genetic analysis was performed at the Molecular Medicine Center, Medical University, Sofia, supported by an infrastructure Grant DUNK01-2/2009 by the National Science Fund, Ministry of Education, Youth and Science.

References

J. J. O'Shea, A. Ma, and P. Lipsky, “Cytokines and autoimmunity,” Nature Reviews Immunology, vol. 2, no. 1, pp. 37–45, 2002.

J. K. Tarlow, A. I. F. Blakemore, A. Lennard et al., “Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat,” Human Genetics, vol. 91, no. 4, pp. 403–404, 1993.

M. Dale and M. J. H. Nicklin, “Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1 IL1RL2 (IL-1Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human chromosome 2q,” Genomics, vol. 57, no. 1, pp. 177–179, 1999.

D. M. Chang, “Interleukin-1 and interleukin-1 receptor antagonist in systemic lupus erythematosus,” Immunological Investigations, vol. 26, no. 5-7, pp. 649–659, 1997.

G. S. Baird and T. J. Montine, “Multiplex immunoassay analysis of cytokines in idiopathic inflammatory myopathy,” Archives of Pathology & Laboratory Medicine, vol. 132, no. 2, pp. 232–238, 2008.

C. Gabay, F. Gay-Croisier, P. Roux-Lombard et al., “Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis: a biologic marker of disease activity with a possible role in the lack of acute-phase protein response,” Arthritis and Rheumatism, vol. 37, no. 12, pp. 1744–1751, 1994.

B. Brugos, E. Kiss, C. Dul et al., “Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease,” Human Immunology, vol. 71, no. 9, pp. 874–877, 2010.

K. Son, Y. Tomita, T. Shimizu, S. Nishinarita, S. Sawada, and T. Horie, “Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis,” Internal Medicine, vol. 39, no. 2, pp. 128–135, 2000.

A. M. Prieur, A. Dayer, P. Roux-Lombard, and J. M. Dayer, “Levels of cytokine inhibitors: a possible marker of disease activity in childhood dermatomyositis and polymyositis,” Clinical and Experimental Rheumatology, vol. 15, no. 2, pp. 211–214, 1997.

A. Bohan and J. B. Peter, “Polymyositis and dermatomyositis,” The New England Journal of Medicine, vol. 292, no. 7, pp. 344–347, 1975.

A. Bohan and J. B. Peter, “Polymyositis and dermatomyositis II,” The New England Journal of Medicine, vol. 292, no. 8, pp. 403–407, 1975.

I. N. Targoff, F. W. Miller, T. A. Medsger Jr., and C. V. Oddis, “Classification criteria for the idiopathic inflammatory myopathies,” Current Opinion in Rheumatology, vol. 9, no. 6, pp. 527–535, 1997.

S. S. Witkin, S. Gerber, and W. J. Ledger, “Influence of interleukin-1 receptor antagonist gene polymorphism on disease,” Clinical Infectious Diseases, vol. 34, no. 2, pp. 204–209, 2002.

A. I. F. Blakemore, J. K. Tarlow, M. J. Cork, C. Gordon, P. Emery, and G. W. Duff, “Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 37, no. 9, pp. 1380–1385, 1994.

H. Suzuki, Y. Matsui, and H. Kashiwagi, “Interleukin-1 receptor antagonist gene polymorphism in Japanese patients with systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 40, no. 2, pp. 389–390, 1997.

C.-M. Huang, M.-C. Wu, J.-Y. Wu, and F.-J. Tsai, “Interleukin-1 receptor antagonist gene polymorphism in Chinese patients with systemic lupus erythematosus,” Clinical Rheumatology, vol. 21, no. 3, pp. 255–257, 2002.

C. G. Parks, G. S. Cooper, M. A. Dooley et al., “Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population based study in the southeastern United States,” Annals of the Rheumatic Diseases, vol. 63, no. 1, pp. 91–94, 2004.

F. Tjernström, G. Hellmer, O. Nived, L. Truedsson, and G. Sturfelt, “Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus,” Lupus, vol. 8, no. 2, pp. 103–108, 1999.

G. G. Song, J. H. Kim, Y. H. Seo, S. J. Choi, J. D. Ji, and Y. H. Lee, “Associations between interleukin 1 polymorphisms and susceptibility to systemic lupus erythematosus: a meta-analysis,” Human Immunology, vol. 75, no. 1, pp. 105–112, 2014.

T. P. Lau, L. H. Lian, S. Y. Tan, and K. H. Chua, “VNTR polymorphisms of the IF-1RN gene: IL-1RN∗1 allele and the susceptibility of SLE in the Malaysian population,” International Journal of Biomedical and Pharmaceutical Sciences, vol. 2, no. 1, pp. 32–37, 2009.

J. Heward, A. Allahabadia, C. Gordon et al., “The interleukin-1 receptor antagonist gene shows no allelic association with three autoimmune diseases,” Thyroid, vol. 9, no. 6, pp. 627–628, 1999.

S. D'Alfonso, M. Rampi, D. Bocchio, G. Colombo, R. Scorza-Smeraldi, and P. Momigliano-Richardi, “Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10,” Arthritis & Rheumatism, vol. 43, no. 1, pp. 120–128, 2000.

V. A. Danis, M. Millington, Q. Huang, V. Hyland, and D. Grennan, “Lack of association between an interleukin-1 receptor antagonist gene polymorphism and systemic lupus erythematosus,” Disease Markers, vol. 12, no. 2, pp. 135–139, 1995.

M. Mohammadoo-Khorasani, S. Salimi, E. Tabatabai, M. Sandoughi, and Z. Zakeri, “Association of interleukin-1 receptor antagonist gene 86bp VNTR polymorphism with systemic lupus erythematosus in south east of Iran,” Zahedan Journal of Research in Medical Sciences, vol. 16, no. 12, pp. 51–54, 2014.

P. K. Manchanda, H. K. Bid, and R. D. Mittal, “Ethnicity greatly influences the interleukin-1 gene cluster(IL-1b promoter, exon-5 and IL-1Ra) polymorphisms: a pilot study of a north Indian population,” Asian Pacific Journal of Cancer Prevention, vol. 6, no. 4, pp. 541–546, 2005.

A. Jönsen, A. A. Bengtsson, G. Sturfelt, and L. Truedsson, “Analysis of HLA DR, HLA DQ, C4A, FcgammaRIIa, FcgammaRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcgammaRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility.,” Arthritis research & therapy., vol. 6, no. 6, pp. R557–562, 2004.

N. J. Camp, A. Cox, F. S. di Giovine, D. McCabe, W. Rich, and G. W. Duff, “Evidence of a pharmacogenomic response to interleukin-1 receptor antagonist in rheumatoid arthritis,” Genes and Immunity, vol. 6, no. 6, pp. 467–471, 2005.

L. G. Rider, C. M. Artlett, C. B. Foster et al., “Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies,” Clinical & Experimental Immunology, vol. 121, no. 1, pp. 47–52, 2000.